Tibolone: Selective tissue estrogen activity regulator utilization in postmenopausal women

David F. Archer, J. C. Gallagher

Research output: Chapter in Book/Report/Conference proceedingChapter


Tibolone is a safe and effective therapy in early menopausal women. Its indications for use are several. It is effective in treating vasomotor symptoms. It causes some endometrial bleeding in the first few months, but this decreases during the first year more than on estrogen. Despite the bleeding, endometrial biopsies show no evidence of endometrial stimulation and there has been no evidence of endometrial hyperplasia or cancer after 2 years. It also has the advantage over selective estrogen receptor modulators (SERMs) of increasing the vaginal maturation value. At the 1.25 mg dose, tibolone is highly effective in preventing bone loss in women in the early postmenopausal years, and early reports suggest that this dose can prevent fractures in older women. In general, tibolone is well tolerated, and there has been no increase in the risk of cardiovascular events or venous thrombosis in younger postmenopausal women. In women in their mid-60s, tibolone increases the risk of stroke in the 1.25 mg dose, and although it appears to reduce fractures, the risk/benefit ratio of the 1.25 mg dose has to be taken into consideration in older women.

Original languageEnglish (US)
Title of host publicationMenopause
PublisherElsevier Inc.
Number of pages6
ISBN (Print)9780123694430
StatePublished - 2007

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology


Dive into the research topics of 'Tibolone: Selective tissue estrogen activity regulator utilization in postmenopausal women'. Together they form a unique fingerprint.

Cite this